Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.

Dushay J, Gao C, Gopalakrishnan GS, Crawley M, Mitten EK, Wilker E, Mullington J, Maratos-Flier E

Diabetes care31 Oct 2011Cited by 96 (Europe PMC)

PMID22040840PMCIDPMC3241299DOI10.2337/dc11-0931PepBankPUB-22040840

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In obese women without diabetes, exenatide reduced weight versus weight gain with placebo.
In plain wordsIn obese women without diabetes, exenatide reduced weight compared with weight gain during placebo treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight change
Study
n = 41
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
Weight change
−2.49 kg
exenatide
Weight change
0.43 kg
placebo
Source sentences
Summary
Subjects treated with exenatide lost an average of 2.49 ± 0.66 kg compared with a 0.43 ± 0.63 kg weight gain during placebo treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period.
Report a problemFND-2204084001
02HumanRandomized controlled trialEfficacy outcome
In obese women without diabetes, weight loss with exenatide was evident at 2 weeks.
In plain wordsIn obese women without diabetes, weight loss during exenatide treatment was evident at 2 weeks.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseEarly weight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 2 weeksAs given in this study (human).
Source sentences
Summary
Weight loss with exenatide treatment was noted at 2 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period.
Report a problemFND-2204084002
03HumanRandomized controlled trialEfficacy outcome
In obese women without diabetes, 30% were high responders to exenatide, losing ≥5% body weight with mean change -7.96 ± 0.52%.
In plain wordsIn obese women without diabetes, 30% lost ≥5% body weight during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHigh weight-loss responders
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
High responders
30%
exenatide
Weight change
−7.96%
high responders
Source sentences
Summary
A total of 30% of subjects were high responders who lost ≥5% body weight (-7.96 ± 0.52%), 39% were moderate responders who lost <5% body weight (-2.43 ± 0.45%), and 31% were nonresponders who gained weight (1.93 ± 0.53%).
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period.
Report a problemFND-2204084003
04HumanRandomized controlled trialEfficacy outcome
In obese women without diabetes, 39% were moderate exenatide responders, losing <5% body weight with mean change -2.43 ± 0.45%.
In plain wordsIn obese women without diabetes, 39% lost <5% body weight during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseModerate weight-loss responders
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
Moderate responders
39%
exenatide
Weight change
−2.43%
moderate responders
Source sentences
Summary
A total of 30% of subjects were high responders who lost ≥5% body weight (-7.96 ± 0.52%), 39% were moderate responders who lost <5% body weight (-2.43 ± 0.45%), and 31% were nonresponders who gained weight (1.93 ± 0.53%).
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period.
Report a problemFND-2204084004
05HumanRandomized controlled trialEfficacy outcome
In obese women without diabetes, 31% were nonresponders who gained weight during exenatide treatment (mean change 1.93 ± 0.53%).
In plain wordsIn obese women without diabetes, 31% were nonresponders who gained weight during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableWeight-gain nonresponders
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
Nonresponders
31%
exenatide
Weight change
1.93%
nonresponders
Source sentences
Summary
A total of 30% of subjects were high responders who lost ≥5% body weight (-7.96 ± 0.52%), 39% were moderate responders who lost <5% body weight (-2.43 ± 0.45%), and 31% were nonresponders who gained weight (1.93 ± 0.53%).
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period.
Report a problemFND-2204084005
06HumanRandomized controlled trialEfficacy outcome
In obese women without diabetes, waist circumference decreased significantly during exenatide treatment.
In plain wordsIn obese women without diabetes, waist circumference decreased significantly during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWaist circumference
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
Waist circumference also decreased significantly with exenatide treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period.
Report a problemFND-2204084006
07HumanRandomized controlled trialSafety outcome
In obese women without diabetes, nausea was more frequent with exenatide than placebo.
In plain wordsIn obese women without diabetes, nausea was more frequent with exenatide than placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseNausea frequency
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
Subjects experienced more nausea during exenatide treatment compared with placebo, but the severity decreased over time and did not correlate with weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period.
Report a problemFND-2204084007
08HumanRandomized controlled trialSafety outcome
In obese women without diabetes, nausea severity decreased over time during exenatide treatment.
In plain wordsIn obese women without diabetes, nausea became less severe over time during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseNausea severity over time
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
Subjects experienced more nausea during exenatide treatment compared with placebo, but the severity decreased over time and did not correlate with weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period.
Report a problemFND-2204084008
09HumanRandomized controlled trialOther
In obese women without diabetes, nausea severity during exenatide treatment did not correlate with weight loss.
In plain wordsIn obese women without diabetes, nausea severity during exenatide treatment was not linked to weight loss.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeNausea severity and weight loss correlation
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
Subjects experienced more nausea during exenatide treatment compared with placebo, but the severity decreased over time and did not correlate with weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period.
Report a problemFND-2204084009

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT00456885

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

Beth Israel Deaconess Medical Centern = 41Apr 2007 to Sept 2010

Obesity · Impaired Glucose Tolerance

Trial page ClinicalTrials.govUpdated 11 Sept 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.